Day: August 10, 2021

IRVINE, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial results for its second quarter ended June 30, 2021. Second Quarter Revenue and Business Highlights:Treated a record number of patients, with revenue of $63.5 million for the second quarter of 2021, up 11% sequentially and 150% year-over-year. Announced FDA clearance of FlowSaver, enabling bloodless thrombectomy with the use of Triever Catheters. Presented interim results of the CLOUT DVT registry at New Cardiovascular Horizons, confirming best in class safety, clot removal, and clinical results for patients treated with ClotTriever. Ended the quarter with $176.1...

DetermaRx Q2 Sample Volume Grows 23% over Q1 2021 Potential pan-cancer utility of DetermaIO strengthened by data in breast, lung, bladder and renal cell cancer, validating the test in all four tumor types evaluated; upcoming oral presentation of randomized clinical trial in TNBC at ESMO Chronix acquisition positions Oncocyte to enter growing field of blood-based monitoring for immune therapy response and transplant rejection testing Conference Call to be held today at 4:30 pm ET/ 1:30 pm PDT  IRVINE, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) — Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer, reports financial results for the second quarter...

12-week Data Readout from ALT-801 Phase 1 Clinical Trial Expected in September        Approximately $218 Million in Cash and Short-Term Investments to Advance Obesity and Liver Disease Pipeline GAITHERSBURG, Md., Aug. 10, 2021 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three- and six-months ending June 30, 2021 and provided a corporate update. “Following data readouts in Q2, Altimmune has focused its efforts on our NASH and emerging obesity pipeline with the encouraging interim data from the ALT-801 Phase 1 trial reinforcing the potential of these programs,” remarked Vipin K. Garg, Ph.D., President and Chief Executive Officer at Altimmune. “Our strong financial position enables us to proceed with a robust ALT-801 development program in...

FREMONT, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) — Enovix Corporation (“Enovix”) (Nasdaq: ENVX, ENVXW), the leader in the design and manufacture of next generation 3D Silicon™ Lithium-ion batteries, today posted to its website at https://ir.enovix.com a quarterly shareholder letter containing the financial results for the second quarter of 2021, ending June 30. The shareholder letter provides a business update that details progress made in the quarter along several key areas including technology, production and commercialization. “We enter the second half of 2021 focused on executing our plan to deliver batteries to category-leading customers with industry-leading energy densities,” said Harrold Rust, President, Chief Executive Officer and Co-Founder of Enovix. “We have made tremendous progress in equipping our first advanced production...

UBX1325 demonstrates favorable tolerability in Phase 1 safety study and improvement in visual acuity and central subfield thickness in majority of patients with diabetic macular edema (DME) and wet age-related macular degeneration (AMD) Results from Phase 1 study of UBX1325 in additional patients with wet AMD expected by end of year UBX1325 Phase 2a proof-of-concept study enrolling patients with DME; data expected first half of 2022 SOUTH SAN FRANCISCO, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the second quarter ended June 30, 2021. “This quarter has been exciting and productive, marked by the compelling data from the Phase 1 study of UBX1325. In addition...

Harrold Rust, President and Chief Executive Officer of EnovixHarrold Rust, President and Chief Executive Officer of Enovix at the Enovix factory in Fremont, CaliforniaFREMONT, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) — Enovix Corporation (“Enovix”) (Nasdaq: ENVX, ENVXW), the leader in the design and manufacture of next generation 3D Silicon™ Lithium-ion batteries, announced today it achieved a key manufacturing facility milestone, completing equipment installation of its first U.S.-based advanced battery production line. Enovix also announced it signed a Master Purchase Agreement and a Cooperation Agreement with a California-based technology leader focused initially on the wearable device space. Based on the terms of the agreements, Enovix will receive a manufacturing capacity reservation fee and pre-payments totaling...

INDIANAPOLIS, Aug. 10, 2021 (GLOBE NEWSWIRE) — POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, today announced the completion of enrollment and initial dosing of the 25-patient safety and dosimetry lead-in of the Company’s Phase 3 SPLASH study evaluating PNT2002 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). “Patient enrollment and initial dosing was completed significantly ahead of schedule,” said Dr. Joe McCann, Chief Executive Officer of POINT Biopharma. “I am incredibly proud of our team for this achievement, especially considering it occurred during an unprecedented global pandemic. I believe the speed of enrollment further highlights the caliber of POINT’s team, as well as the unmet need of...

Q2 2021 End of Period Subscribers of 4.9 millionQ2 2021 End of Period Digital Subscribers up 6% year-over-year to an all-time Q2-end highQ2 2021 Revenues of $311 millionQ2 2021 Gross Margin of 60%; excluding one-time charges, Q2 2021 adjusted gross margin increased 100 basis points year-over-year to 61%FY 2021 Guidance: Revenues approaching $1.3 billion and GAAP EPS in the range of $1.10 to $1.25, which incorporates an approximately $0.53 aggregate negative impact from the early extinguishment of debt and estimated restructuring charges in 2021NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) — WW International, Inc. (NASDAQ: WW) today announced its results for the second quarter of fiscal 2021. “We ended the quarter with 4.9 million subscribers, including 4.1 million Digital subscribers — an all-time second quarter-end...

SANTA BARBARA, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) — Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company exclusively focused on plastic surgery, today announced its financial results for the second quarter ended June 30, 2021. Second Quarter 2021 Financial HighlightsRecord Breast Products revenue of $20.1 million, a 116% year-over-year increase10% sequential growth over the first quarter of 2021 80% growth over the second quarter of 2019Cash of $82.4 million as of June 30, 2021, a $2 million increase from March 31, 2021 Updated full year 2021 guidance for revenues expected to range from $74 to $78 million, representing 35%-42% growth year-over-yearRecent Business HighlightsAdded more than 300 accounts in the second quarter, achieving a new record base of more than 2,400 accounts Generated...